Gout

Richard Conway RichardPAConway
4 years 11 months ago
Is diet important in gout control? #ACR20 @rheumnow

Olga Petryna DrPetryna
4 years 11 months ago
@RheumNow #acr20 abs0665 claim based database stdy of pegloticase/immunomodulation coadministration trends: use of co-immunomodulation ⬆️ from 1.2%-3.9% 2015- 2018 to 15.0% in 2019. 86%start immunomodulator within 30 days of first peg infusion. MTX most commonly used
ACR20 convergence highlights a shift in gout management and uric acid lowering therapy (ULT). The new biologics pegdriticase and pegloticase are associated with risk of immunogenicity and loss of biological effects.

Olga Petryna DrPetryna
4 years 11 months ago
@RheumNow #acr20 abs0690 ph2a trial: potent reduction of sUA w/URAT1 inhibitor AA882. 100% of pts sUA levels < 6 mg/dL &63% pts < 5 mg/dL compared to febuxostat 50% & 13% respectively. Even more remarkable reduction w/ AA882+febuxostat. Mild to moderate SEs. https://t.co/XrDJXEoC1j


Olga Petryna DrPetryna
4 years 11 months ago
@RheumNow #acr20 abs0600 a case control stdy of 545 CHF exacerbate admissions: pts w/gout flares median LoS 10 d vs 6 d w/out flare or gout at all. log LoS w gout flare 2.41 ± 0.96 vs 1.77 ± 0.90 w/out, p < 0.0001. Prevention of gout flares in CHF pts of essence #ACRbest https://t.co/8xiHHYxvsC


Dr. John Cush RheumNow
4 years 11 months ago
RheumNow’s expanded coverage of the #ACR20 Annual meeting is sponsored in part by @bmsnews, @HorizonNews, @SanofiGenzyme, @Novartis. All content chosen by RheumNow and its Faculty.

Olga Petryna DrPetryna
4 years 11 months ago
@RheumNow #acr20 abs 0649 PROTECT trial of pegloticase in 7 kidney transplant pts w/uncontrolled gout: 2-12 infusions, 2+immunosuppressants on board for transplant care. No change in eGFR, HAQ pain ⬇️by 33.8 at wk20. Alb/cr improved by >35%in 2pts. sUA< 1 mg/dL, no serious AEs https://t.co/f4tnFjMTe8



Richard Conway RichardPAConway
4 years 11 months ago
Dr Peral reports on intracellular crystal containing vacuoles in gout and CPP arthritis. Crystal containing vacuoles only seen in CPP arthritis. @rheumnow #ACR20 Abstr#666 https://t.co/ITQMXhjQt0


Richard Conway RichardPAConway
4 years 11 months ago
Dr Vargas-Santos reported on risk of gout with SGLT2-inhibitors using THIN database. Canagliflozin shown in prior RCT to reduce gout risk. Here dapagliflozin and empagliflozin showed even stronger effect @rheumnow #ACR20 Abstr#660 https://t.co/MTjByMmHo7


Richard Conway RichardPAConway
4 years 11 months ago
Dr Minalyan and colleagues report rates of gout flare following hospital admission of patients prescribed allopurinol. Gout flare 14 times more likely if allopurinol stopped or omitted. @rheumnow #ACR20 Abstr#688 https://t.co/x3eyX1PLFB


Richard Conway RichardPAConway
4 years 11 months ago
Dr McCormick reports sequential patterns of gout flare from the Boston Online Gout Study. Second attack most likely to affect ipsilateral same joint, and second most likely contralateral same joint. @rheumnow #ACR20 Abstr#672 https://t.co/2AAMvcOCk8


Dr. John Cush RheumNow
4 years 11 months ago
Get the highlights on the opening day of #ACR20. Listen in to faculty reports and overviews. Follow the link below or find us on Apple podcasts under RheumNow Podcast.
https://t.co/qDQzCAHsHi https://t.co/9nM19ZdHQQ


Richard Conway RichardPAConway
4 years 11 months ago
Dr Murdoch and colleagues report “An Apple Pie a Day Does Not Keep the Doctor Away”. An analysis of the negative depictions of gout in tv and film and how this may affect our care. @rheumnow #ACR20 Abstr#646 https://t.co/BBW0Fd5kHE

Advanced Imaging for Crystal Arthritis: Which Test is Best? Dr. Nicola Dalbeth
Dr. Nicola Dalbeth of Aukland, New Zealand examines abstracts #0647 and #1542 involving imaging studies for crystal arthritis at ACR 2020.